Antitumor activity of nivolumab on hemodialysis after renal allograft rejection

Journal for ImmunoTherapy of Cancer

Volumn 4, Issue 1, 2016, Pages

  Ong, Michael ^a,b   Ibrahim, Andrea Marie ^b   Bourassa Blanchette, Samuel ^a   Canil, Christina ^a   Fairhead, Todd ^a   Knoll, Greg ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Acute allograft rejection; Anti PD 1 therapy; Hemodialysis; Melanoma; Nivolumab; Organ transplant

Indexed keywords

BASILIXIMAB; CREATININE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; NIVOLUMAB; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; TACROLIMUS; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ABDOMINAL PAIN; ADULT; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIABETIC KETOACIDOSIS; DRUG DOSE REDUCTION; ENDOBRONCHIAL ULTRASONOGRAPHY; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPERPIGMENTATION; KIDNEY ALLOGRAFT REJECTION; LETHARGY; LOOSE FECES; LUNG NODULE; LYMPHOSCINTIGRAPHY; MALAISE; METASTATIC MELANOMA; MIDDLE AGED; NAUSEA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEROID THERAPY; VOMITING; ANTAGONISTS AND INHIBITORS; CANCER STAGING; COMPLICATION; GRAFT REJECTION; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; LUNG TUMOR; MELANOMA; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SECONDARY; SKIN TUMOR; X-RAY COMPUTED TOMOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; DIABETES MELLITUS, TYPE 1; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LUNG NEOPLASMS; MELANOMA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PROGRAMMED CELL DEATH 1 RECEPTOR; RENAL DIALYSIS; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84997794621     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-016-0171-8     Document Type: Article

References (25)

1. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54. doi: 10.1056/NEJMoa1200690.
2. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-13. doi: 10.1056/NEJMoa1510665.
3. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer. 2009;125(8):1747-54. doi: 10.1002/ijc.24439.
4. Morales RE, Shoushtari AN, Walsh MM, Grewal P, Lipson EJ, Carvajal RD. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunother Cancer. 2015;3(22). doi: 10.1186/s40425-015-0066-0.
5. Ranganath HA, Panella TJ. Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma. J Immunother. 2015;38(5):211. doi: 10.1097/CJI.0000000000000077.
6. Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol. 2014;32(19):e69-71. doi: 10.1200/JCO.2013.49.2314.
7. Lipson EJ, Bagnasco SM, Moore J, Jang S, Patel MJ, Zachary AA, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med. 2016;374(9):896-8. doi: 10.1056/NEJMc1509268.
8. Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol. 2016;27(6):1135-7. doi: 10.1093/annonc/mdw130.
9. Alhamad T, Venkatachalam K, Linette GP, Brennan DC. Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection. Am J Transplant. 2016;16(4):1332-3. doi: 10.1111/ajt.13711.
10. Boils CL, Aljadir DN, Cantafio AW. Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy. Am J Transplant. 2016. doi: 10.1111/ajt.13786.
11. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624.
12. TM (nivolumab) Product Monograph. Montreal, Canada: Bristol-Myers Squibb Canada. 2016:1-65. http://www.bmscanada.ca/static/products/en/pm_pdf/OPDIVO_EN_PM.pdf. Accessed 18 Jul 2016.
13. Janus N, Launay-Vacher V, Deray G, Islam MS, Thyss A, Thariat J. Management of targeted therapies in hemodialysis patients. Bull Cancer. 2012;99(3):381-8. doi: 10.1684/bdc.2011.1484.
14. Jillella AP, Dainer PM, Kallab AM, Ustun C. Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituxumab is not eliminated by hemodialysis. Am J Hematol. 2002;71(3):219-22. doi: 10.1002/ajh.10213.
15. Riella LV, Patterson AM, Sharpe AH, Chandraker A. Role of the PD-1 pathway in the immune response. Am J Transplant. 2012;12(10):2575-87. doi: 10.1111/j.1600-6143.2012.04224.x.
16. Robert C, Schachter J, Long GV, Arance A, Grob JJ, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521-32. doi: 10.1056/NEJMoa1503093.
17. Pike R, Thomas N, Workman S, Ambrose L, Guzman D, et al. PD-1 expressing T cell subsets modify the rejection risk in renal transplant patients. Front Immunol. 2016;7:126. doi: 10.3389/fimmu.2016.00126.
18. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681-91. doi: 10.1056/NEJMra022137.
19. Dahlke E, Murray CA, Kitchen J, Chan A-W. Systematic review of melanoma incidence and prognosis in solid organ transplant recipients. Transplant Res. 2014;3:10. doi: 10.1186/2047-1440-3-10.
20. Brewer JD, Christenson LJ, Weaver AL, Dapprich DC, Weenig RH, Lim KK, et al. Malignant melanoma in solid transplant recipients. Arch Dertmatol. 2011;147(7):790-6. doi: 10.1001/archdermatol.2011.159.
21. Riella LV, Watanabe T, Sage PT, Yang J, Yeung M, Azzi J, et al. Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts. Am J Transplant. 2011;11(4):832-40. doi: 10.1111/j.1600-6143.2011.03451.x.
22. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234-40. doi: 10.1001/jamaoncol.2015.4368.
23. Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374:333-43. doi: 10.1056/NEJMoa1506027.
24. del Rio M-L, Buhler L, Gibbons C, Tian J, Rodriguez-Barbosa J-I. PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. Transpl Int. 2008;21(11):1015-28. doi: 10.1111/j.1432-2277.2008.00726.x.
25. Geissler EK. Post-transplantation malignancies: here today, gone tomorrow? Nat Rev Clin Oncol. 2015;12(12):705-17. doi: 10.1038/nrclinonc.2015.186.